SlideShare a Scribd company logo
2/12/2013




PHARMACOLOGY
INTRO DEFINATION

  Zulcaif Ahmad


                              1
2/12/2013




TOPIC
1)   Bioavailability
2)   Bioequivalence
3)   Therapeutic index
4)   Plasma half life
5)   Dose response curve
6)   Area under curve (AUC)
7)   Volume of distribution

                                          2
2/12/2013




PHARMACOKINETICS

    Pharmakon ( drug )
    Kinetics ( motion )
 Definition : The actions of the body on an
  administered drug ( dose concentration ).
          It involves drug absorption ,
  distribution , metabolism and elimination .



                                                3
2/12/2013




PHARMACOKINETICS




                               4
2/12/2013




                        Pharmacokinetics
                           conc. vs time
Conc.(mg/L)




              0.0

                    0                                  25


                            Time (h)


                                                            5
2/12/2013




1) BIOAVAILABILITY
   In pharmacology, bioavailability is a measurement of the rate and extent to
    which a drug reaches the systemic circulation It is denoted by the letter f

   Bioavailability is the ratio of the area calculated for oral route of
    administration to the intravenous route of administration.

   In pharmacology, bioavailability (BA) is a subcategory of absorption and is
    the fraction of an administered dose of unchanged drug that reaches
    the systemic circulation, one of the principal pharmacokinetic properties
    of drugs. By definition, when a medication is administered intravenously, its
    bioavailability is 100%.

   However, when a medication is administered via other routes (such as
    orally), its bioavailability generally decreases (due to incomplete absorption
    and first-pass metabolism) or may vary from patient to patient.

   Bioavailability is one of the essential tools in pharmacokinetics, as
    bioavailability must be considered when calculating dosages for non-
    intravenous routes of administration.


                                                                                     6
2/12/2013




For a non-intravenous drug , it is less than
 100% because of :
        1) Absorption Parameters.
        2)First-pass elimination.
 Bioavailability is the drug proportion that
 actually reaches systemic circulation .



                                                7
2/12/2013




            8
2/12/2013




2) BIOEQUIVALENCE
 Relationship between 2 preparations of the
  same drug at same dose in same form with
  similar bioavailability.
                 OR
 The relationship between two preparations of
  the same drug in the same dosage form that
  have a similar bioavailability.


                                             9
2/12/2013




   Bioequivalence is a term in pharmacokinetics used to assess the
    expected in vivo biological equivalence of two proprietary
    preparations of a drug. If two products are said to be bioequivalent it
    means that they would be expected to be, for all intents and
    purposes, the same.

   two pharmaceutical products are bioequivalent if they are
    pharmaceutically equivalent and their bioavailabilities (rate and
    extent of availability) after administration in the same molar dose are
    similar to such a degree that their effects, with respect to both
    efficacy and safety, can be expected to be essentially the same.

   Pharmaceutical equivalence implies the same amount of the same
    active substance(s), in the same dosage form, for the same route of
    administration and meeting the same or comparable standards."[1]


                                                                          10
2/12/2013




GRAPH SHOWING BIOEQUIVALENCE

                         90
                         80
                   mL)




                         70
 Concentration (ng/




                         60
                                                                         Test/Generic
                         50
                                                                         Reference/Brand
                         40
                         30
                         20
                         10
                         0
                              0   5   10       15         20   25   30
                                           Time (hours)

                                                                                           11
2/12/2013




3) THERAPEUTIC INDEX
 The difference between the minimum
  therapeutic and minimum toxic
  concentrations of a drug.
 Therapeutic index represents the safety of
  a drug.
 Drugs having low therapeutic index include:


    Anticonvulsants, lithium,     anticoagulants,
    corticosteroids and cardio active drugs.

                                                12
2/12/2013




   therapeutic index (also known as therapeutic ratio)
    is a comparison of the amount of a therapeutic agent
    that causes the therapeutic effect to the amount that
    causes death (in animal studies) or toxicity (in human
    studies).
   the ratio between the dosage of a drug that causes a
    lethal effect and the dosage that causes therapeutic
    effect.
   Medical Dictionary :
     The ratio between the toxic dose and the therapeutic
    dose of a drug, used as a measure of the relative
    safety of the drug for a particular treatment.

                                                         13
2/12/2013




4) PLASMA HALF LIFE
   The duration of action of a drug is known as its half life.

   This is the period of time required for the concentration or amount of
    drug in the body to be reduced by one-half.

   Drug can be eliminated from the body, or it can be translocated to
    another body fluid compartment such as the intracellular fluid or it can
    be destroyed in the blood after it is reduced to half life.

    The removal of a drug from the plasma is known as clearance and the
    distribution of the drug in the various body tissues is known as
    the volume of distribution. Both of these pharmacokinetic parameters
    are important in determining the half life of a drug.

   Here is the symbol to represent the half-life: t½


                                                                               14
2/12/2013




 The biological half-life or elimination half-
  life of a substance is the time it takes for a
  substance (for example
  a metabolite, drug, signaling molecule,
  radioactive nuclide, or other substance) to lose
  half of its pharmacologic, physiologic, or
  radiologic activity , as per the MeSH definition.
 Biological half-life is an
  important pharmacokinetic parameter .

                                                      15
2/12/2013




            16
2/12/2013




5) DOSE-RESPONSE CURVE
   A dose–response curve is a simple X–Y graph relating the magnitude of a stressor ( e.g.
    amount of drug ) to the response of receptor.

   The measured dose (usually in milligrams, micrograms, or grams per kilogram of body-
    weight for oral exposures or milligrams per cubic meter of ambient air for inhalation
    exposures) is generally plotted on the X axis and the response is plotted on the Y axis.

   The dose–response relationship , describes the change in effect on an organism caused
    by differing levels of exposure (or doses) to a stressor (usually a chemical) after a certain
    exposure time.[1] This may apply to individuals (e.g.: a small amount has no significant
    effect, a large amount is fatal), or to populations (e.g.: how many people or organisms are
    affected at different levels of exposure).

   Studying dose response, and developing dose response models, is central to determining
    "safe" and "hazardous" levels and dosages for drugs, potential pollutants, and other
    substances to which humans or other organisms are exposed. These conclusions are often
    the basis for public policy.

   Dose–response relationships generally depend on the exposure time and exposure route
    (e.g., inhalation, dietary intake); quantifying the response after a different exposure time or
    for a different route leads to a different relationship and possibly different conclusions on
    the effects of the stressor under consideration.




                                                                                                      17
2/12/2013




6) AREA     UNDER CURVE (AUC)
 The area under the plot of plasma concentration
  of drug (not logarithm of the concentration)
  against time after drug administration
 The area under the plasma (serum, or blood)
  concentration versus time curve (AUC) has a
  number of important uses in pharmacokinetics.
 The AUC is of particular use in estimating
  bioavailability of drugs, and in estimating total
  clearance of drugs (ClT).

                                                  18
2/12/2013




            19
2/12/2013




   AUC can be used as a measure of drug exposure. It is
    derived from drug concentration and time so it gives a
    measure how much - how long a drug stays in a body.

   The AUC measured after administration of a drug product
    is an important parameter in the comparison of drug
    products. These bioequivalence or bioavailability
    studies can be analyzed by comparing AUC values.

   Drug AUC values can be used to determine other
    pharmacokinetic parameters, such as clearance or
    bioavailability, F. Similar techniques can be used to
    calculate area under the first moment curve (AUMC)

                                                             20
2/12/2013




7) VOLUME                 OF DISTRIBUTION
   Volume of distribution is the measure of the apparent space in the
    body available to contain the drug.

   Volume of distribution relates the amount of drug in the body to the
    concentration of drug in blood or plasma .

   Formula for volume of distribution is , total amount of drug in the
    body divided by drug blood plasma concentration.

   It is not a real but a theoretical volume.

   if VD is greater, it shows that the drug is more diluted than it should
    be (in the blood plasma), meaning more of it is distributed in tissue
    (i.e. not in plasma).

    It is defined as the distribution of a medication between plasma and
    the rest of the body after oral or parenteral dosing.
                                                                              21
2/12/2013




   Volume of distribution may be increased
    by renal failure (due to fluid retention)
    and liver failure (due to altered body fluid).

   Conversely it may be decreased in
    dehydration.




                                                     22
2/12/2013




            23
2/12/2013




REFERENCE
 http://bipolar.about.com/od/medications/g/gl_bio
  availabil.htm
 http://faculty.ksu.edu.sa/hisham/Documents/Stu
  dents/a_PHCL/pkin08.pdf
 http://www.wisegeek.com/what-is-
  bioequivalence.htm#did-you-know
 Stedman's medical dictionary .
 Medical-dictionary.thefreemedicaldictionary.com
 www.freedictionry.com


                                                 24
2/12/2013




THANK YOU…




                         25
2/12/2013




ANY QUESTION ???



                               26

More Related Content

What's hot

Introduction to pharmacokinetics and pharmacodynamics principles
Introduction to pharmacokinetics and pharmacodynamics principlesIntroduction to pharmacokinetics and pharmacodynamics principles
Introduction to pharmacokinetics and pharmacodynamics principles
pooranachithra flowry
 
Drug distribution
Drug distributionDrug distribution
Drug distribution
Naser Tadvi
 
First pass metabolism- Buddhabhushan dongre
First pass metabolism- Buddhabhushan dongreFirst pass metabolism- Buddhabhushan dongre
First pass metabolism- Buddhabhushan dongre
BUDDHABHUSHAN DONGRE
 
Clinical pharmacokinetics part 1 dr jayesh vaghela
Clinical pharmacokinetics part 1 dr jayesh vaghelaClinical pharmacokinetics part 1 dr jayesh vaghela
Clinical pharmacokinetics part 1 dr jayesh vaghela
jpv2212
 
Absorption of drugs
Absorption of drugsAbsorption of drugs
Absorption of drugs
Dr Nikita Ingale
 
Genetic polymorphism in drug metabolism
Genetic polymorphism in drug metabolismGenetic polymorphism in drug metabolism
Genetic polymorphism in drug metabolism
M.Arumuga Vignesh
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
akash mahadev
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
Dr. Ramesh Bhandari
 
Estimation of pharmacokinetic parameters
Estimation of pharmacokinetic parametersEstimation of pharmacokinetic parameters
Estimation of pharmacokinetic parameters
Karun Kumar
 
Pharmacokinetics lecture notes pharmacology
Pharmacokinetics lecture notes pharmacologyPharmacokinetics lecture notes pharmacology
Pharmacokinetics lecture notes pharmacologyNunkoo Raj
 
Drug metabolism
Drug metabolism Drug metabolism
Drug metabolism
Dr Swaroop HS
 
Compartment modeling
Compartment modelingCompartment modeling
Compartment modeling
SHILPI BISWAS
 
clinical pharmacokinetics
clinical pharmacokineticsclinical pharmacokinetics
clinical pharmacokinetics
mubarek ahmedin
 
Absorption Pharmacokinetics.pptx
Absorption Pharmacokinetics.pptxAbsorption Pharmacokinetics.pptx
Absorption Pharmacokinetics.pptx
FarazaJaved
 
Induction and Inhibition of Drug Metabolism Inhibition of Biliary Excretion
Induction and Inhibition of Drug Metabolism Inhibition of Biliary ExcretionInduction and Inhibition of Drug Metabolism Inhibition of Biliary Excretion
Induction and Inhibition of Drug Metabolism Inhibition of Biliary Excretion
Dr B Naga Raju
 
Dosage regimen
Dosage regimenDosage regimen
Pharmacokinetics / Biopharmaceutics - drug absorption
Pharmacokinetics / Biopharmaceutics - drug absorptionPharmacokinetics / Biopharmaceutics - drug absorption
Pharmacokinetics / Biopharmaceutics - drug absorption
Areej Abu Hanieh
 
CONCEPT OF LOADING AND MAINTAINANCE DOSE.pptx
CONCEPT OF LOADING AND MAINTAINANCE DOSE.pptxCONCEPT OF LOADING AND MAINTAINANCE DOSE.pptx
CONCEPT OF LOADING AND MAINTAINANCE DOSE.pptx
NamrataSawant19
 
Elimination
EliminationElimination
Elimination
Kailas Mali
 

What's hot (20)

Introduction to pharmacokinetics and pharmacodynamics principles
Introduction to pharmacokinetics and pharmacodynamics principlesIntroduction to pharmacokinetics and pharmacodynamics principles
Introduction to pharmacokinetics and pharmacodynamics principles
 
Drug distribution
Drug distributionDrug distribution
Drug distribution
 
First pass metabolism- Buddhabhushan dongre
First pass metabolism- Buddhabhushan dongreFirst pass metabolism- Buddhabhushan dongre
First pass metabolism- Buddhabhushan dongre
 
Clinical pharmacokinetics part 1 dr jayesh vaghela
Clinical pharmacokinetics part 1 dr jayesh vaghelaClinical pharmacokinetics part 1 dr jayesh vaghela
Clinical pharmacokinetics part 1 dr jayesh vaghela
 
Absorption of drugs
Absorption of drugsAbsorption of drugs
Absorption of drugs
 
Genetic polymorphism in drug metabolism
Genetic polymorphism in drug metabolismGenetic polymorphism in drug metabolism
Genetic polymorphism in drug metabolism
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
 
Estimation of pharmacokinetic parameters
Estimation of pharmacokinetic parametersEstimation of pharmacokinetic parameters
Estimation of pharmacokinetic parameters
 
Pharmacokinetics lecture notes pharmacology
Pharmacokinetics lecture notes pharmacologyPharmacokinetics lecture notes pharmacology
Pharmacokinetics lecture notes pharmacology
 
Drug metabolism
Drug metabolism Drug metabolism
Drug metabolism
 
Compartment modeling
Compartment modelingCompartment modeling
Compartment modeling
 
clinical pharmacokinetics
clinical pharmacokineticsclinical pharmacokinetics
clinical pharmacokinetics
 
Absorption Pharmacokinetics.pptx
Absorption Pharmacokinetics.pptxAbsorption Pharmacokinetics.pptx
Absorption Pharmacokinetics.pptx
 
Induction and Inhibition of Drug Metabolism Inhibition of Biliary Excretion
Induction and Inhibition of Drug Metabolism Inhibition of Biliary ExcretionInduction and Inhibition of Drug Metabolism Inhibition of Biliary Excretion
Induction and Inhibition of Drug Metabolism Inhibition of Biliary Excretion
 
Dosage regimen
Dosage regimenDosage regimen
Dosage regimen
 
Pharmacokinetics / Biopharmaceutics - drug absorption
Pharmacokinetics / Biopharmaceutics - drug absorptionPharmacokinetics / Biopharmaceutics - drug absorption
Pharmacokinetics / Biopharmaceutics - drug absorption
 
Bioavailability ppt
Bioavailability pptBioavailability ppt
Bioavailability ppt
 
CONCEPT OF LOADING AND MAINTAINANCE DOSE.pptx
CONCEPT OF LOADING AND MAINTAINANCE DOSE.pptxCONCEPT OF LOADING AND MAINTAINANCE DOSE.pptx
CONCEPT OF LOADING AND MAINTAINANCE DOSE.pptx
 
Elimination
EliminationElimination
Elimination
 

Viewers also liked

Dose response relationship
Dose response relationshipDose response relationship
Dose response relationship
mohamed sanooz
 
4. pharmacokinetics and pharmacodynamics of gamithromycin
4. pharmacokinetics and pharmacodynamics of gamithromycin4. pharmacokinetics and pharmacodynamics of gamithromycin
4. pharmacokinetics and pharmacodynamics of gamithromycinMerial EMEA
 
Dose response
Dose responseDose response
Dose response
Dr Rekha Arya
 
Perfect exposure & composition
Perfect exposure & compositionPerfect exposure & composition
Perfect exposure & composition
Noushad P
 
Drug interactionppt
Drug interactionpptDrug interactionppt
Drug interactionpptUE
 
Lecture 1 6 2010-1
Lecture 1 6 2010-1Lecture 1 6 2010-1
Lecture 1 6 2010-1mobb2x
 
An introduction to dermal exposure assessment
An introduction to dermal exposure assessmentAn introduction to dermal exposure assessment
An introduction to dermal exposure assessment
Retired
 
Pharmacokinetics: Lecture four
Pharmacokinetics: Lecture four Pharmacokinetics: Lecture four
Pharmacokinetics: Lecture four
Anas Bahnassi أنس البهنسي
 
A guide to exposure determination and the impact of artwork
A guide to exposure determination and the impact of artworkA guide to exposure determination and the impact of artwork
A guide to exposure determination and the impact of artwork
William Shorter
 
Exposure Basics: Learn to Correctly Expose Your Photographs
Exposure Basics: Learn to Correctly Expose Your PhotographsExposure Basics: Learn to Correctly Expose Your Photographs
Exposure Basics: Learn to Correctly Expose Your Photographs
Don Hazelwood
 
Bioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence StudiesBioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence StudiesDr. Kunal Chitnis
 
Health Effects Of Radiation Exposure
Health Effects Of Radiation ExposureHealth Effects Of Radiation Exposure
Health Effects Of Radiation Exposurefondas vakalis
 
Radiographic exposure and image quality
Radiographic exposure and image qualityRadiographic exposure and image quality
Radiographic exposure and image qualityRad Tech
 
Environment protection act
Environment protection actEnvironment protection act
Environment protection actPadmapriyaG
 
Foreign exchange risk and exposure
Foreign exchange risk and exposureForeign exchange risk and exposure
Foreign exchange risk and exposure
Kanchan Kandel
 
Build Features, Not Apps
Build Features, Not AppsBuild Features, Not Apps
Build Features, Not Apps
Natasha Murashev
 

Viewers also liked (17)

Dose response relationship
Dose response relationshipDose response relationship
Dose response relationship
 
4. pharmacokinetics and pharmacodynamics of gamithromycin
4. pharmacokinetics and pharmacodynamics of gamithromycin4. pharmacokinetics and pharmacodynamics of gamithromycin
4. pharmacokinetics and pharmacodynamics of gamithromycin
 
Dose response
Dose responseDose response
Dose response
 
Perfect exposure & composition
Perfect exposure & compositionPerfect exposure & composition
Perfect exposure & composition
 
Drug interactionppt
Drug interactionpptDrug interactionppt
Drug interactionppt
 
Lecture 1 6 2010-1
Lecture 1 6 2010-1Lecture 1 6 2010-1
Lecture 1 6 2010-1
 
An introduction to dermal exposure assessment
An introduction to dermal exposure assessmentAn introduction to dermal exposure assessment
An introduction to dermal exposure assessment
 
Pharmacokinetics: Lecture four
Pharmacokinetics: Lecture four Pharmacokinetics: Lecture four
Pharmacokinetics: Lecture four
 
A guide to exposure determination and the impact of artwork
A guide to exposure determination and the impact of artworkA guide to exposure determination and the impact of artwork
A guide to exposure determination and the impact of artwork
 
Exposure Basics: Learn to Correctly Expose Your Photographs
Exposure Basics: Learn to Correctly Expose Your PhotographsExposure Basics: Learn to Correctly Expose Your Photographs
Exposure Basics: Learn to Correctly Expose Your Photographs
 
Lecture 1 & 2 Strategic Hrm 2006
Lecture 1 & 2   Strategic Hrm 2006Lecture 1 & 2   Strategic Hrm 2006
Lecture 1 & 2 Strategic Hrm 2006
 
Bioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence StudiesBioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence Studies
 
Health Effects Of Radiation Exposure
Health Effects Of Radiation ExposureHealth Effects Of Radiation Exposure
Health Effects Of Radiation Exposure
 
Radiographic exposure and image quality
Radiographic exposure and image qualityRadiographic exposure and image quality
Radiographic exposure and image quality
 
Environment protection act
Environment protection actEnvironment protection act
Environment protection act
 
Foreign exchange risk and exposure
Foreign exchange risk and exposureForeign exchange risk and exposure
Foreign exchange risk and exposure
 
Build Features, Not Apps
Build Features, Not AppsBuild Features, Not Apps
Build Features, Not Apps
 

Similar to Pharmacology introduction defination

Pharmacokinetics / Biopharmaceutics - Bioavailability and Bioequivalence
Pharmacokinetics / Biopharmaceutics - Bioavailability and BioequivalencePharmacokinetics / Biopharmaceutics - Bioavailability and Bioequivalence
Pharmacokinetics / Biopharmaceutics - Bioavailability and Bioequivalence
Areej Abu Hanieh
 
Bioavailabilityand bioequivalence
Bioavailabilityand bioequivalenceBioavailabilityand bioequivalence
Bioavailabilityand bioequivalence
harvestmoneyonline makemoney
 
Bioavailability and bioequivalence of Drug Product.docx
Bioavailability and bioequivalence of Drug Product.docxBioavailability and bioequivalence of Drug Product.docx
Bioavailability and bioequivalence of Drug Product.docx
abhisheksinghcompute
 
BioavailabilityandBioequivalence.pdf
BioavailabilityandBioequivalence.pdfBioavailabilityandBioequivalence.pdf
BioavailabilityandBioequivalence.pdf
abhisheksinghcompute
 
Area Under the Curve (Pharmacokinetics)
Area Under the Curve (Pharmacokinetics)Area Under the Curve (Pharmacokinetics)
Area Under the Curve (Pharmacokinetics)
Maulana Sakti
 
Clinical pharmacology.Basics.
Clinical pharmacology.Basics.Clinical pharmacology.Basics.
Clinical pharmacology.Basics.
Eugene Shorikov
 
toxicokinetics-1.pptx
toxicokinetics-1.pptxtoxicokinetics-1.pptx
toxicokinetics-1.pptx
Unnatikhare1
 
Biopharmaceutics
BiopharmaceuticsBiopharmaceutics
Biopharmaceutics
Sa Na
 
Experimental and clinical validation of classical and proproetary ayurvedic f...
Experimental and clinical validation of classical and proproetary ayurvedic f...Experimental and clinical validation of classical and proproetary ayurvedic f...
Experimental and clinical validation of classical and proproetary ayurvedic f...Nani Karnam Vinayakam
 
Introduction to pharmacokinetics and pharmacodynamics drug interaction
Introduction to pharmacokinetics and pharmacodynamics drug interactionIntroduction to pharmacokinetics and pharmacodynamics drug interaction
Introduction to pharmacokinetics and pharmacodynamics drug interaction
RuchiRawat13
 
Pharmacotherapeutics chapter 1 topic 1.pptx
Pharmacotherapeutics chapter 1 topic 1.pptxPharmacotherapeutics chapter 1 topic 1.pptx
Pharmacotherapeutics chapter 1 topic 1.pptx
Alka187671
 
Toxicology
ToxicologyToxicology
Toxicology
Roushan Thakur
 
Pharma 2016
Pharma 2016Pharma 2016
Pharma 2016
Khalid Aftab, Ph.D.
 
Introduction to Biopharmaceutics
Introduction to Biopharmaceutics Introduction to Biopharmaceutics
Introduction to Biopharmaceutics
Mani Vasakam
 
BA_in_drugs_and_factors_which_modified.pdf
BA_in_drugs_and_factors_which_modified.pdfBA_in_drugs_and_factors_which_modified.pdf
BA_in_drugs_and_factors_which_modified.pdf
NoemiBecerraTello
 
introduction to biopharmaceutics
introduction to biopharmaceutics introduction to biopharmaceutics
introduction to biopharmaceutics
Tehmina Adnan
 
What is a drug
What is a drugWhat is a drug
What is a drug
Takeen Khurshid
 
Bioavailability and Bioequivalence Studies (BABE) & Concept of Biowaivers
Bioavailability and Bioequivalence Studies (BABE) & Concept of BiowaiversBioavailability and Bioequivalence Studies (BABE) & Concept of Biowaivers
Bioavailability and Bioequivalence Studies (BABE) & Concept of Biowaivers
Jaspreet Guraya
 
Types of equivalent and measurement of bioavailability
Types of equivalent and measurement of bioavailabilityTypes of equivalent and measurement of bioavailability
Types of equivalent and measurement of bioavailabilitySonam Gandhi
 

Similar to Pharmacology introduction defination (20)

Pharmacokinetics / Biopharmaceutics - Bioavailability and Bioequivalence
Pharmacokinetics / Biopharmaceutics - Bioavailability and BioequivalencePharmacokinetics / Biopharmaceutics - Bioavailability and Bioequivalence
Pharmacokinetics / Biopharmaceutics - Bioavailability and Bioequivalence
 
Bioavailabilityand bioequivalence
Bioavailabilityand bioequivalenceBioavailabilityand bioequivalence
Bioavailabilityand bioequivalence
 
Bioavailability and bioequivalence of Drug Product.docx
Bioavailability and bioequivalence of Drug Product.docxBioavailability and bioequivalence of Drug Product.docx
Bioavailability and bioequivalence of Drug Product.docx
 
BioavailabilityandBioequivalence.pdf
BioavailabilityandBioequivalence.pdfBioavailabilityandBioequivalence.pdf
BioavailabilityandBioequivalence.pdf
 
Babe bppk
Babe bppkBabe bppk
Babe bppk
 
Area Under the Curve (Pharmacokinetics)
Area Under the Curve (Pharmacokinetics)Area Under the Curve (Pharmacokinetics)
Area Under the Curve (Pharmacokinetics)
 
Clinical pharmacology.Basics.
Clinical pharmacology.Basics.Clinical pharmacology.Basics.
Clinical pharmacology.Basics.
 
toxicokinetics-1.pptx
toxicokinetics-1.pptxtoxicokinetics-1.pptx
toxicokinetics-1.pptx
 
Biopharmaceutics
BiopharmaceuticsBiopharmaceutics
Biopharmaceutics
 
Experimental and clinical validation of classical and proproetary ayurvedic f...
Experimental and clinical validation of classical and proproetary ayurvedic f...Experimental and clinical validation of classical and proproetary ayurvedic f...
Experimental and clinical validation of classical and proproetary ayurvedic f...
 
Introduction to pharmacokinetics and pharmacodynamics drug interaction
Introduction to pharmacokinetics and pharmacodynamics drug interactionIntroduction to pharmacokinetics and pharmacodynamics drug interaction
Introduction to pharmacokinetics and pharmacodynamics drug interaction
 
Pharmacotherapeutics chapter 1 topic 1.pptx
Pharmacotherapeutics chapter 1 topic 1.pptxPharmacotherapeutics chapter 1 topic 1.pptx
Pharmacotherapeutics chapter 1 topic 1.pptx
 
Toxicology
ToxicologyToxicology
Toxicology
 
Pharma 2016
Pharma 2016Pharma 2016
Pharma 2016
 
Introduction to Biopharmaceutics
Introduction to Biopharmaceutics Introduction to Biopharmaceutics
Introduction to Biopharmaceutics
 
BA_in_drugs_and_factors_which_modified.pdf
BA_in_drugs_and_factors_which_modified.pdfBA_in_drugs_and_factors_which_modified.pdf
BA_in_drugs_and_factors_which_modified.pdf
 
introduction to biopharmaceutics
introduction to biopharmaceutics introduction to biopharmaceutics
introduction to biopharmaceutics
 
What is a drug
What is a drugWhat is a drug
What is a drug
 
Bioavailability and Bioequivalence Studies (BABE) & Concept of Biowaivers
Bioavailability and Bioequivalence Studies (BABE) & Concept of BiowaiversBioavailability and Bioequivalence Studies (BABE) & Concept of Biowaivers
Bioavailability and Bioequivalence Studies (BABE) & Concept of Biowaivers
 
Types of equivalent and measurement of bioavailability
Types of equivalent and measurement of bioavailabilityTypes of equivalent and measurement of bioavailability
Types of equivalent and measurement of bioavailability
 

More from Zulcaif Ahmad

Pharmacokinetics & Pharmacodynamic models, Tolerance, Hypersensitivity response
Pharmacokinetics & Pharmacodynamic models, Tolerance, Hypersensitivity responsePharmacokinetics & Pharmacodynamic models, Tolerance, Hypersensitivity response
Pharmacokinetics & Pharmacodynamic models, Tolerance, Hypersensitivity response
Zulcaif Ahmad
 
Magnetically Modulated DDS
Magnetically Modulated DDSMagnetically Modulated DDS
Magnetically Modulated DDS
Zulcaif Ahmad
 
Analgesic, Pain Ladder, Pain Assessment & Pain Treatment
Analgesic, Pain Ladder, Pain Assessment & Pain TreatmentAnalgesic, Pain Ladder, Pain Assessment & Pain Treatment
Analgesic, Pain Ladder, Pain Assessment & Pain Treatment
Zulcaif Ahmad
 
Solubility & Method for determination of solubility
Solubility & Method for determination of solubility  Solubility & Method for determination of solubility
Solubility & Method for determination of solubility
Zulcaif Ahmad
 
Autonomic Nervous System drugs classification
Autonomic Nervous System drugs classificationAutonomic Nervous System drugs classification
Autonomic Nervous System drugs classification
Zulcaif Ahmad
 
Drug (Anti-Psychotic drug) Induce Parkinsonism
Drug (Anti-Psychotic drug) Induce ParkinsonismDrug (Anti-Psychotic drug) Induce Parkinsonism
Drug (Anti-Psychotic drug) Induce Parkinsonism
Zulcaif Ahmad
 
Alcohol Induce Liver Injury
Alcohol Induce Liver InjuryAlcohol Induce Liver Injury
Alcohol Induce Liver Injury
Zulcaif Ahmad
 
Drug induce hepatitis
Drug induce hepatitisDrug induce hepatitis
Drug induce hepatitis
Zulcaif Ahmad
 
Pulmonary hypertension
Pulmonary hypertensionPulmonary hypertension
Pulmonary hypertension
Zulcaif Ahmad
 
Macrolides and lincosamide
Macrolides and lincosamideMacrolides and lincosamide
Macrolides and lincosamide
Zulcaif Ahmad
 
Chopramphenicol
ChopramphenicolChopramphenicol
Chopramphenicol
Zulcaif Ahmad
 
Immunosuppressants
ImmunosuppressantsImmunosuppressants
Immunosuppressants
Zulcaif Ahmad
 
Anthelmintics Pharmacology
Anthelmintics PharmacologyAnthelmintics Pharmacology
Anthelmintics Pharmacology
Zulcaif Ahmad
 
Quinolones
QuinolonesQuinolones
Quinolones
Zulcaif Ahmad
 
Cancer chemotherapy
Cancer chemotherapyCancer chemotherapy
Cancer chemotherapy
Zulcaif Ahmad
 
Asthma
Asthma Asthma
Asthma
Zulcaif Ahmad
 
Evaporation presentation
Evaporation presentationEvaporation presentation
Evaporation presentation
Zulcaif Ahmad
 
Audit community pharmacy
Audit community pharmacyAudit community pharmacy
Audit community pharmacy
Zulcaif Ahmad
 
Quality Management
Quality ManagementQuality Management
Quality Management
Zulcaif Ahmad
 
Dispensing of controlled substances
Dispensing of controlled substancesDispensing of controlled substances
Dispensing of controlled substances
Zulcaif Ahmad
 

More from Zulcaif Ahmad (20)

Pharmacokinetics & Pharmacodynamic models, Tolerance, Hypersensitivity response
Pharmacokinetics & Pharmacodynamic models, Tolerance, Hypersensitivity responsePharmacokinetics & Pharmacodynamic models, Tolerance, Hypersensitivity response
Pharmacokinetics & Pharmacodynamic models, Tolerance, Hypersensitivity response
 
Magnetically Modulated DDS
Magnetically Modulated DDSMagnetically Modulated DDS
Magnetically Modulated DDS
 
Analgesic, Pain Ladder, Pain Assessment & Pain Treatment
Analgesic, Pain Ladder, Pain Assessment & Pain TreatmentAnalgesic, Pain Ladder, Pain Assessment & Pain Treatment
Analgesic, Pain Ladder, Pain Assessment & Pain Treatment
 
Solubility & Method for determination of solubility
Solubility & Method for determination of solubility  Solubility & Method for determination of solubility
Solubility & Method for determination of solubility
 
Autonomic Nervous System drugs classification
Autonomic Nervous System drugs classificationAutonomic Nervous System drugs classification
Autonomic Nervous System drugs classification
 
Drug (Anti-Psychotic drug) Induce Parkinsonism
Drug (Anti-Psychotic drug) Induce ParkinsonismDrug (Anti-Psychotic drug) Induce Parkinsonism
Drug (Anti-Psychotic drug) Induce Parkinsonism
 
Alcohol Induce Liver Injury
Alcohol Induce Liver InjuryAlcohol Induce Liver Injury
Alcohol Induce Liver Injury
 
Drug induce hepatitis
Drug induce hepatitisDrug induce hepatitis
Drug induce hepatitis
 
Pulmonary hypertension
Pulmonary hypertensionPulmonary hypertension
Pulmonary hypertension
 
Macrolides and lincosamide
Macrolides and lincosamideMacrolides and lincosamide
Macrolides and lincosamide
 
Chopramphenicol
ChopramphenicolChopramphenicol
Chopramphenicol
 
Immunosuppressants
ImmunosuppressantsImmunosuppressants
Immunosuppressants
 
Anthelmintics Pharmacology
Anthelmintics PharmacologyAnthelmintics Pharmacology
Anthelmintics Pharmacology
 
Quinolones
QuinolonesQuinolones
Quinolones
 
Cancer chemotherapy
Cancer chemotherapyCancer chemotherapy
Cancer chemotherapy
 
Asthma
Asthma Asthma
Asthma
 
Evaporation presentation
Evaporation presentationEvaporation presentation
Evaporation presentation
 
Audit community pharmacy
Audit community pharmacyAudit community pharmacy
Audit community pharmacy
 
Quality Management
Quality ManagementQuality Management
Quality Management
 
Dispensing of controlled substances
Dispensing of controlled substancesDispensing of controlled substances
Dispensing of controlled substances
 

Recently uploaded

ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Effective-Soaps-for-Fungal-Skin-Infections.pptx
Effective-Soaps-for-Fungal-Skin-Infections.pptxEffective-Soaps-for-Fungal-Skin-Infections.pptx
Effective-Soaps-for-Fungal-Skin-Infections.pptx
SwisschemDerma
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
NEHA GUPTA
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
AkankshaAshtankar
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Lighthouse Retreat
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Vision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of opticsVision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of optics
Sai Sailesh Kumar Goothy
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 

Recently uploaded (20)

ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Effective-Soaps-for-Fungal-Skin-Infections.pptx
Effective-Soaps-for-Fungal-Skin-Infections.pptxEffective-Soaps-for-Fungal-Skin-Infections.pptx
Effective-Soaps-for-Fungal-Skin-Infections.pptx
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
Vision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of opticsVision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of optics
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 

Pharmacology introduction defination

  • 2. 2/12/2013 TOPIC 1) Bioavailability 2) Bioequivalence 3) Therapeutic index 4) Plasma half life 5) Dose response curve 6) Area under curve (AUC) 7) Volume of distribution 2
  • 3. 2/12/2013 PHARMACOKINETICS Pharmakon ( drug ) Kinetics ( motion )  Definition : The actions of the body on an administered drug ( dose concentration ). It involves drug absorption , distribution , metabolism and elimination . 3
  • 5. 2/12/2013 Pharmacokinetics conc. vs time Conc.(mg/L) 0.0 0 25 Time (h) 5
  • 6. 2/12/2013 1) BIOAVAILABILITY  In pharmacology, bioavailability is a measurement of the rate and extent to which a drug reaches the systemic circulation It is denoted by the letter f  Bioavailability is the ratio of the area calculated for oral route of administration to the intravenous route of administration.  In pharmacology, bioavailability (BA) is a subcategory of absorption and is the fraction of an administered dose of unchanged drug that reaches the systemic circulation, one of the principal pharmacokinetic properties of drugs. By definition, when a medication is administered intravenously, its bioavailability is 100%.  However, when a medication is administered via other routes (such as orally), its bioavailability generally decreases (due to incomplete absorption and first-pass metabolism) or may vary from patient to patient.  Bioavailability is one of the essential tools in pharmacokinetics, as bioavailability must be considered when calculating dosages for non- intravenous routes of administration. 6
  • 7. 2/12/2013 For a non-intravenous drug , it is less than 100% because of : 1) Absorption Parameters. 2)First-pass elimination.  Bioavailability is the drug proportion that actually reaches systemic circulation . 7
  • 9. 2/12/2013 2) BIOEQUIVALENCE  Relationship between 2 preparations of the same drug at same dose in same form with similar bioavailability. OR  The relationship between two preparations of the same drug in the same dosage form that have a similar bioavailability. 9
  • 10. 2/12/2013  Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same.  two pharmaceutical products are bioequivalent if they are pharmaceutically equivalent and their bioavailabilities (rate and extent of availability) after administration in the same molar dose are similar to such a degree that their effects, with respect to both efficacy and safety, can be expected to be essentially the same.  Pharmaceutical equivalence implies the same amount of the same active substance(s), in the same dosage form, for the same route of administration and meeting the same or comparable standards."[1] 10
  • 11. 2/12/2013 GRAPH SHOWING BIOEQUIVALENCE 90 80 mL) 70 Concentration (ng/ 60 Test/Generic 50 Reference/Brand 40 30 20 10 0 0 5 10 15 20 25 30 Time (hours) 11
  • 12. 2/12/2013 3) THERAPEUTIC INDEX  The difference between the minimum therapeutic and minimum toxic concentrations of a drug.  Therapeutic index represents the safety of a drug.  Drugs having low therapeutic index include: Anticonvulsants, lithium, anticoagulants, corticosteroids and cardio active drugs. 12
  • 13. 2/12/2013  therapeutic index (also known as therapeutic ratio) is a comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes death (in animal studies) or toxicity (in human studies).  the ratio between the dosage of a drug that causes a lethal effect and the dosage that causes therapeutic effect.  Medical Dictionary : The ratio between the toxic dose and the therapeutic dose of a drug, used as a measure of the relative safety of the drug for a particular treatment. 13
  • 14. 2/12/2013 4) PLASMA HALF LIFE  The duration of action of a drug is known as its half life.  This is the period of time required for the concentration or amount of drug in the body to be reduced by one-half.  Drug can be eliminated from the body, or it can be translocated to another body fluid compartment such as the intracellular fluid or it can be destroyed in the blood after it is reduced to half life.  The removal of a drug from the plasma is known as clearance and the distribution of the drug in the various body tissues is known as the volume of distribution. Both of these pharmacokinetic parameters are important in determining the half life of a drug.  Here is the symbol to represent the half-life: t½ 14
  • 15. 2/12/2013  The biological half-life or elimination half- life of a substance is the time it takes for a substance (for example a metabolite, drug, signaling molecule, radioactive nuclide, or other substance) to lose half of its pharmacologic, physiologic, or radiologic activity , as per the MeSH definition.  Biological half-life is an important pharmacokinetic parameter . 15
  • 16. 2/12/2013 16
  • 17. 2/12/2013 5) DOSE-RESPONSE CURVE  A dose–response curve is a simple X–Y graph relating the magnitude of a stressor ( e.g. amount of drug ) to the response of receptor.  The measured dose (usually in milligrams, micrograms, or grams per kilogram of body- weight for oral exposures or milligrams per cubic meter of ambient air for inhalation exposures) is generally plotted on the X axis and the response is plotted on the Y axis.  The dose–response relationship , describes the change in effect on an organism caused by differing levels of exposure (or doses) to a stressor (usually a chemical) after a certain exposure time.[1] This may apply to individuals (e.g.: a small amount has no significant effect, a large amount is fatal), or to populations (e.g.: how many people or organisms are affected at different levels of exposure).  Studying dose response, and developing dose response models, is central to determining "safe" and "hazardous" levels and dosages for drugs, potential pollutants, and other substances to which humans or other organisms are exposed. These conclusions are often the basis for public policy.  Dose–response relationships generally depend on the exposure time and exposure route (e.g., inhalation, dietary intake); quantifying the response after a different exposure time or for a different route leads to a different relationship and possibly different conclusions on the effects of the stressor under consideration. 17
  • 18. 2/12/2013 6) AREA UNDER CURVE (AUC)  The area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration  The area under the plasma (serum, or blood) concentration versus time curve (AUC) has a number of important uses in pharmacokinetics.  The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs (ClT). 18
  • 19. 2/12/2013 19
  • 20. 2/12/2013  AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much - how long a drug stays in a body.  The AUC measured after administration of a drug product is an important parameter in the comparison of drug products. These bioequivalence or bioavailability studies can be analyzed by comparing AUC values.  Drug AUC values can be used to determine other pharmacokinetic parameters, such as clearance or bioavailability, F. Similar techniques can be used to calculate area under the first moment curve (AUMC) 20
  • 21. 2/12/2013 7) VOLUME OF DISTRIBUTION  Volume of distribution is the measure of the apparent space in the body available to contain the drug.  Volume of distribution relates the amount of drug in the body to the concentration of drug in blood or plasma .  Formula for volume of distribution is , total amount of drug in the body divided by drug blood plasma concentration.  It is not a real but a theoretical volume.  if VD is greater, it shows that the drug is more diluted than it should be (in the blood plasma), meaning more of it is distributed in tissue (i.e. not in plasma).  It is defined as the distribution of a medication between plasma and the rest of the body after oral or parenteral dosing. 21
  • 22. 2/12/2013  Volume of distribution may be increased by renal failure (due to fluid retention) and liver failure (due to altered body fluid).  Conversely it may be decreased in dehydration. 22
  • 23. 2/12/2013 23
  • 24. 2/12/2013 REFERENCE  http://bipolar.about.com/od/medications/g/gl_bio availabil.htm  http://faculty.ksu.edu.sa/hisham/Documents/Stu dents/a_PHCL/pkin08.pdf  http://www.wisegeek.com/what-is- bioequivalence.htm#did-you-know  Stedman's medical dictionary .  Medical-dictionary.thefreemedicaldictionary.com  www.freedictionry.com 24

Editor's Notes

  1. which can, in many respects, be envisioned more accurately as the actions of the body on an administered drug. It includes studies of the mechanisms of drug absorption, distribution, metabolism, and excretion; onset of action; duration of effect; biotransformation; and effects and routes of excretion of the metabolites of the drug. Pharmacokinetics determine how rapidly and for how long the drug will apear at the target organ.
  2. . the degree to which a drug or other substance becomes available to the target tissue after administration. A measure of the amount of drug that is actually absorbed from a given dose. the degree to which a drug or other substance becomes available to the target tissue after administration. Clinical pharmacology The degree to which a drug is available to a target tissue after administration which, for oral drugs, reflects the rate and extent of GI tract absorption; BA is the in vivo presence of a substance in a form that allows it to be metabolized, serve as a substrate, bind a specific molecule, or participate in biochemical reactions. For dietary supplements, herbs and other nutrients in which the route of administration is nearly always oral, bioavailability generally designates simply the quantity or fraction of the ingested dose that is absorbed.[2]Bioavailability is defined slightly differently for drugs as opposed to dietary supplements primarily due to the method of administration and Food and Drug Administration regulations.Bioaccessibility is a concept related to bioavailability in the context of biodegradation and environmental pollution. A molecule (often a persistent organic pollutant) is said to be bioavailable when "[it] is available to cross an organism’s cellular membrane from the environment, if the organism has access to the chemical." 
  3. Absorption parameters : gastrointestinal track.
  4. BioequivalenceIn determining bioequivalence, for example, between two products such as a commercially-available Brand product and a potential to-be-marketed Generic product, pharmacokinetic studies are conducted whereby each of the preparations are administered in a cross-over study to volunteer subjects, generally healthy individuals but occasionally in patients. Serum/plasma samples are obtained at regular intervals and assayed for parent drug (or occasionally metabolite) concentration. Occasionally, blood concentration levels are neither feasible or possible to compare the two products (e.g. inhaled corticosteroids), then pharmacodynamic endpoints rather than pharmacokinetic endpoints (see below) are used for comparison. For a pharmacokinetic comparison, the plasma concentration data are used to assess key pharmacokinetic parameters such as area under the curve (AUC), peak concentration (Cmax), time to peak concentration (Tmax), and absorption lag time (tlag). Testing should be conducted at several different doses, especially when the drug displays non-linear pharmacokinetics.In addition to data from bioequivalence studies, other data may need to be submitted to meet regulatory requirements for bioequivalence. Such evidence may include:1. analytical method validation2. In vitro-in vivo correlation studies(IVIVC)
  5. Establish that a new formulation has therapeutic equivalence in the rate and extent of absorption to the reference drug product.Generic drug : a medication sold under its generic name ; usully legal only after the patent has expired or if no patent was issued for the substance . Generic drugs are usually less expensive than proprietry medication .
  6. Anti-convulsants : a drug that relieves or prevent convulsions, A type of drug given to prevent seizures ,some patients with migrines can be treated effectively with an anti-convulsants. ( conulsions : an involuntry contraction or series of contraction of the voluntry muscles ).Anti-coagulants : substance that prevents coagulation of blood .Corticosteroids : Cardio-active drug :
  7. the ratio between the dosage of a drug that causes a lethal effect and the dosage that causes atherapeutic effect.Medical Dictionarytherapeutic index n.  The ratio between the toxic dose and the therapeutic dose of a drug, used as a measure of the relativesafety of the drug for a particular treatment.Quantitatively, it is the ratio given by the lethal or toxic dose divided by the therapeutic dose.In animal studies, the therapeutic index is the lethal dose of a drug for 50% of the population (LD50) divided by the minimum effective dose for 50% of the population (ED50).Lethality is not determined in human clinical trials; instead, the dose that produces a toxicity in 50% of the population (TD50) is used to calculate the therapeutic index.While the lethal dose is important to determine in animal studies, there are usually severe toxicities that occur at sublethal doses in humans, and these toxicities often limit the maximum dose of a drug. A higher therapeutic index is preferable to a lower one: a patient would have to take a much higher dose of such a drug to reach the lethal/toxic threshold than the dose taken to elicit the therapeutic effect.
  8. Examples of biological half-lives[edit]WaterThe biological half-life of water in a human is about 7 to 14 days. It can be altered by behavior. Drinking large amounts of alcohol will reduce the biological half-life of water in the body.[3][4] This has been used to decontaminate humans who are internally contaminated with tritiated water (tritium). Drinking the same amount of water would have a similar effect, but many would find it difficult to drink a large volume of water. The basis of this decontamination method (used at Harwell) is to increase the rate at which the water in the body is replaced with new water.[edit]AlcoholThe removal of ethanol (drinking alcohol) through oxidation by alcohol dehydrogenase in the liver from the human body is limited. Hence the removal of a large concentration of alcohol from blood may follow zero-order kinetics. Also the rate-limiting steps for one substance may be in common with other substances. For instance, the blood alcohol concentration can be used to modify the biochemistry of methanol and ethylene glycol. In this way the oxidation of methanol to the toxic formaldehyde and formic acid in the (human body) can be prevented by giving an appropriate amount of ethanol to a person who has ingested methanol. Note that methanol is very toxic and causes blindness and death. A person who has ingested ethylene glycol can be treated in the same way. complex kineticsMetalsThe biological half-life of caesium in humans is between one and four months. This can be shortened by feeding the person prussian blue. The prussian blue in the digestive system acts as a solid ion exchanger which absorbs the caesium while releasing potassium ions.For some substances, it is important to think of the human or animal body as being made up of several parts, each with their own affinity for the substance, and each part with a different biological half-life (physiologically-based pharmacokinetic modelling). Attempts to remove a substance from the whole organism may have the effect of increasing the burden present in one part of the organism. For instance, if a person who is contaminated with lead is given EDTA in a chelation therapy, then while the rate at which lead is lost from the body will be increased, the lead within the body tends to relocate into the brain where it can do the most harm.[citation needed]Polonium in the body has a biological half-life of about 30 to 50 days.Caesium in the body has a biological half-life of about one to four months.Mercury (as methylmercury) in the body has a half-life of about 65 days.Lead in bone has a biological half-life of about ten years.Cadmium in bone has a biological half-life of about 30 years.Plutonium in bone has a biological half-life of about 100 years.Plutonium in the liver has a biological half-life of about 40 years.
  9. MeSH definition : an abbreviations derived from MEDICAL SUBJECT HEADINGS , the list of medical terms used by NATIONAL LIBRARY OF MEDICINE ( NLM ) for its computerized system of storage and retrivel of published medical reports , this system is also used for indexing medical reference published in the monthly and annual volumes of index medicus …16000 terms .
  10. AUC (area-under-the-curve): This is the overall amount of drug in the bloodstream after a dose. AUC studies are often used when researchers are looking for drug-drug or drug-food interactions. The way to get an AUC involves collecting many blood samples (usually every one or two hours) right after a person takes a dose up until the next dose is due. In each blood sample, the concentration of the drug is measured with a machine (discussed later). Then all the drug concentrations are put onto a graph based on the time after the dose that they were collected. A curve is made by connecting the points on the graph. The AUC for that drug is then calculated as the area under this drug concentration curve. An AUC study contains a lot of information about PK. It is probably the best way to understand how people handle a drug (PK).Cmax (maximum concentration): This is the highest concentration of drug in the blood that is measured after a dose. Cmaxusually happens within a few hours after the dose is taken. The time that Cmaxhappens is referred to as Tmax. For some antiretroviral drugs, a high Cmax is thought to increase the risk of side effects from the drug.Cmin or trough (pronounced "troff")(minimum concentration): This is the lowest concentration of the drug in the blood that is measured after a dose. It happens right before a patient takes the next usual dose. It is not known for certain, but many people in the HIV community believe that keeping the trough concentration (Cmin) above a certain level is especially important for anti-HIV activity.
  11. Cmax , The maximum drug concentration. The maximum concentration of drug in the plasma is a function of both the rate and extent of absorption. Cmax will increase with an increase in the dose, as well as with an increase in the absorption rate. 3. Tmax , The time at which the Cmax occurs. The Tmax reflects the rate of drug absorption, and decreases as the absorption rate increases.
  12. Area under first moment curve (AUMC) : plasma drug concentration x time after dosing versus time after drug administration.Mean resident times (MRT) : it is used for linear and non-linear systems.
  13. Lipophilic drug :Hydrophilic drug :